VHL regulates NEK1 via both HIF-2α pathway and ubiquitin-proteasome pathway in renal cancer cell

Area of Science:

• Cell Biology
• Oncology
• Molecular Biology

Background:

• Von Hippel-Lindau (VHL) tumor suppressor and Never-in-mitosis A (NIMA)-related kinase 1 (NEK1) are crucial for primary cilium formation.
• The regulatory relationship between VHL and NEK1, particularly in renal cancer, remains uncharacterized.

Purpose of the Study:

• To investigate the regulatory role of VHL on NEK1 expression and function in renal cancer cells.
• To elucidate the molecular mechanisms underlying VHL-mediated regulation of NEK1.

Main Methods:

• Comparative analysis of NEK1 expression in VHL-wild-type versus VHL-defective renal cancer cell lines.
• VHL overexpression and knockdown experiments.
• Analysis of the NEK1 promoter for hypoxia-response elements (HREs).
• Hypoxia induction studies in vitro and in vivo.
• HIF-1α and HIF-2α knockdown experiments.
• Co-immunoprecipitation to confirm VHL-NEK1 association.
• Assessment of NEK1 protein degradation and ubiquitination.

Main Results:

• VHL-defective renal cancer cells exhibit higher NEK1 levels compared to VHL-wild-type cells.
• VHL overexpression down-regulates NEK1, while VHL knockdown up-regulates NEK1.
• NEK1 possesses an HRE in its promoter, and hypoxia induces NEK1 expression.
• Hypoxia-induced NEK1 upregulation is dependent on HIF-2α, not HIF-1α.
• VHL associates with NEK1 and promotes its protein degradation via ubiquitination.

Conclusions:

• VHL negatively regulates NEK1 expression in renal cancer cells.
• VHL controls NEK1 levels through both the HIF-2α signaling pathway and the ubiquitin-proteasome system.
• These findings reveal a novel regulatory axis involving VHL, HIF-2α, and NEK1 in renal cancer pathogenesis.